Breast Cancer
CDK inhibitors in breast cancer Learning Zone
ASCO 2024 A high-level overview
From ASCO 2024, read Dr Ben Gallarda’s overview of ASCO’s commitment to palliative care, artificial intelligence, and coordination with organizations.
Abemaciclib: a newcomer in the treatment of HR+/HER2− early breast cancer
Abemaciclib, a CDK4/6 inhibitor, is the first adjuvant in 16 years to be added to endocrine therapy for HR+/HER2− early breast cancer and the first of its class to receive FDA and EMA approval for this indication.
Other insight articles
Symposium on refractory multiple myeloma, COMy 2023
Watch our expert panel discussion on the management of relapsed and refractory multiple myeloma (RRMM) in older and frail adults.
How can poor-quality clinical trials impact clinical decision-making?
Explore why a cautious approach is warranted when interpreting trial results.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event